Funding antibiotic innovation with vouchers: Recommendations on how to strengthen a flawed incentive policy

Health Affairs

Volumn 35, Issue 5, 2016, Pages 784-790

  Outterson, Kevin ^a   McDonnell, Anthony ^b  

^a BOSTON UNIVERSITY   (United States)

^b Specialist and Ref Microbiol Div   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; GENERIC DRUG; ANTIINFECTIVE AGENT;

ANTIBIOTIC VOUCHER; ARTICLE; BUDGET; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; FUNDING; GOVERNMENT; HEALTH CARE FINANCING; HEALTH CARE POLICY; HUMAN; INVESTMENT; MONEY; PRACTICE GUIDELINE; REIMBURSEMENT; REWARD; ANTIBIOTIC RESISTANCE; DRUG DEVELOPMENT; ECONOMICS; INVENTION; MOTIVATION; PROCEDURES; SUPPLY AND DISTRIBUTION; UNITED STATES;

ANTI-BACTERIAL AGENTS; DRUG DISCOVERY; DRUG INDUSTRY; DRUG RESISTANCE, MICROBIAL; DRUGS, GENERIC; GOVERNMENT PROGRAMS; HEALTH POLICY; HUMANS; INVENTIONS; MOTIVATION; UNITED STATES;

EID: 84969178650     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2015.1139     Document Type: Article

References (40)

1. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013 [Internet]. Atlanta (GA): CDC; 2013 [cited 2016 Mar 22]. Available from:http://www.cdc.gov/drug resistance/threat-report-2013/pdf/ ar-threats-2013-508.pdf
2. Laxminarayan R, Matsoso P, Pant S, Brower C, Røttingen JA, Klugman K, et al. Access to effective antimicrobials:a worldwide challenge. Lancet. 2016;387(10014):168-75.
3. Review on Antimicrobial Resistance. Securing new drugs for future generations:the pipeline of antibiotics [Internet]. London: Review on Antimicrobial Resistance; 2015 May [cited 2016 Mar 22]. Available from:http://amr-Review.org/sites/ default/files/SECURING%20NEW %20DRUGS%20FOR%20FUTURE %20GENERATIONS%20FINAL %20WEB_0.pdf
4. Mendelson M, Røttingen JA, Gopinathan U, Hamer DH,Wertheim H, Basnyat B, et al. Maximizing access to achieve appropriate human antimicrobial use in low-income and middle-income countries. Lancet. 2016;387(10014):188-98.
5. World Health Organization. Global action plan on antimicrobial resistance [Internet]. Geneva: WHO; 2015 May [cited 2016 Mar 22]. Available from: http://www.who .int/drugresistance/global_action_ plan/en/
6. Innovative Medicines Initiative. New drugs for bad bugs [Internet]. Brussels: IMI; 2015 [cited 2016 Mar 22]. Available from: http://www .imi.europa.eu/content/nd4bb
7. White House. National action plan for combating antibiotic-resistant bacteria [Internet]. Washington (DC): White House; 2015 Mar [cited 2016 Mar 22]. Available from:https://www.whitehouse.gov/sites/ default/files/docs/national_ action_plan_for_combating_ antibotic-resistant_bacteria.pdf
8. G7 Health Ministers. Declaration of the G7 Health Ministers [Internet]. Berlin: G7 Health Ministers Meeting; 2015 Oct 8-9 [cited 2016 Mar 22]. Available from: http:// www.bmg.bund.de/fileadmin/ dateien/Downloads/G/G7-Ges .Minister_2015/G7_Health_ Ministers_Declaration_AMR_ and_EBOLA.pdf
9. Outterson K. New business models for sustainable antibiotics [Internet]. London: Chatham House; 2014 Feb [cited 2016 Mar 22]. Available from: http://www.chathamhouse .org/sites/files/chathamhouse/ public/Research/Global%20Health/0214SustainableAntibiotics.pdf
10. Clift C, Gopinathan U, Morel C, Outterson K, Røttingen JA, So A, editors. Towards a new global business model for antibiotics: delinking revenues from sales [Internet]. London: Chatham House; 2015 Oct [cited 2016 Mar 22]. Available from:https://www.chathamhouse.org/ sites/files/chathamhouse/field/ field_document/20151009New BusinessModelAntibioticsClift GopinathanMorelOutterson RottingenSo.pdf
11. Hoffman SJ, Outterson K, Røttingen JA, Cars O, Clift C, Rizvi Z, et al. An international legal framework to address antimicrobial resistance. Bull World Health Organ. 2015; 93(2):66.
12. White House, Office of the Press Secretary [Internet]. Washington (DC): White House; 2015. Press release, Fact sheet: president's 2016 budget proposes historic investment to combat antibiotic-resistant bacteria to protect public health; 2015 Jan 27 [cited 2016 Mar 22]. Available from: https://www.whitehouse .gov/the-press-office/2015/01/27/ fact-sheet-president-s-2016-budgetproposes- historic-investmentcombat- a
13. Hearing before the Subcommittee on Health, Energy and Commerce Committee, 113th Congress (statement by Adrian Thomas, vice president, Global Market Access and Public Health and head of Global Public Health at Janssen Global Services, the pharmaceutical companies of Johnson and Johnson). 21st century cures: examining ways to combat antibiotic resistance and foster new drug development [Internet]. Washington (DC): Energy and Commerce Committee; 2014 Sep 19 [cited 2016 Mar 22]. Available from: https://energycommerce .house.gov/hearings-and-votes/ hearings/21st-century-curesexamining- ways-combat-antibioticresistance- and
14. Karst KR. The Promoting Life-Saving New Therapies for Neonates Act of 2015: a new twist on transferable vouchers. FDA Law Blog [blog on the Internet]. 2015 Sep 20 [cited 2016 Mar 22]. Available from: http:// www.fdalawblog.net/fda_law_ blog_hyman_phelps/2015/09/thepromoting- life-saving-newtherapies- for-neonates-act-of-2015- a-new-twist-on-transferablevoucher. html
15. President's Council of Advisors on Science and Technology. Report to the president on combating antibiotic resistance [Internet]. Washington (DC): Executive Office of the President; 2014 Sep [cited 2016 Mar 22]. p. 40. Available from:https://www.whitehouse.gov/sites/ default/files/microsites/ostp/ PCAST/pcast_carb_report_ sept2014.pdf
16. Outterson K, Samora JB, Keller-Cuda K.Will longer antimicrobial patents improve global public health? Lancet Infect Dis. 2007;7(8):559-66.
17. Spellberg B. Antibiotic resistance and antibiotic development. Lancet Infect Dis. 2008;8(4):211-2.
18. Kesselheim AS, Outterson K. Improving antibiotic markets for longterm sustainability. Yale J Health Policy Law Ethics. 2011;11(1):101-67.
19. Kesselheim AS, Maggs LR, Sarpatwari A. Experience with the Priority Review Voucher Program for drug development. JAMA. 2015; 314(16):1687-8.
20. Food and Drug Administration. Guidance for industry: Tropical Disease Priority Review Vouchers. Silver Spring (MD): FDA; 2008 Oct. p. 9.
21. Heled Y. Regulatory competitive shelters. Ohio State Law J. 2015; 76(2):299-356.
22. Kesselheim AS. An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences. Milbank Q. 2011;89(3):450-502.
23. To access the Appendix, click on the Appendix link in the box to the right of the article online.
24. Rex JH, Outterson K. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach. Lancet Infect Dis. 2016;16(4):500-5.
25. Sertkaya A, Eyraud J, Birkenbach A, Franz C, Ackerley N, Overton V, et al. Analytical framework for examining the value of antibacterial products [Internet]. Washington (DC): Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation; 2014 Apr [cited 2016 Mar 23]. Available from: http://aspe.hhs.gov/ sp/reports/2014/antibacterials/ rpt_antibacterials.cfm
26. Towse A, Hoyle CK, Goodall J, Hirsch M, Williams E, Mestre-Ferrandiz J, et al. (Office of Health Economics, London, UK). Economics of an insurance model for new antibiotics. (Unpublished article, 2016).
27. Wiggins SN, Maness R. Price competition in pharmaceuticals: the case of anti-infectives. Econ Inq. 2004; 42(2):247-63.
28. Olson LM, Wending BW. Estimating the effect of entry on generic drug prices using Hatch-Waxman exclusivity [Internet]. Washington (DC):Federal Trade Commission; 2013 Apr [cited 2016 Mar 23]. (Bureau of Economics Working Paper No. 317). Available from: https://www.ftc .gov/reports/estimating-effectentry- generic-drug-prices-usinghatch- waxman-exclusivity
29. Outterson K, Powers JH, Daniel GW, McClellan MB. Repairing the broken market for antibiotic innovation. Health Aff (Millwood). 2015;34(2):277-85.
30. Food and Drug Administration Safety and Innovation Act of 2012, Pub. L. No. 112-144, Sec. 908, Rare Pediatric Disease Priority Review Voucher Incentive Program.
31. Adding Ebola to the FDA Priority Review Voucher Program Act of 2014, Pub. L. 113-233.
32. Daulaire N, Bang A, Tomson G, Kalyango JN, Cars O. Universal access to effective antimicrobials: an essential feature of global collective action against antimicrobial resistance. J Law Med Ethics. 2015;43(2) (Special Suppl):17-21.
33. Ardal C, Outterson K, Hoffman SJ, Ghafur A, Sharland M, Ranganathan N, et al. International cooperation to improve access to and sustain effectiveness of antimicrobials. Lancet. 2016;387(10015):296-307.
34. Bessen J, Meurer MJ. Patent failure:how judges, bureaucrats, and lawyers put innovators at risk. Princeton (NJ): Princeton University Press; 2008.
35. Eldred v. Ashcroft, 537 U.S. 186 (2003).
36. United States v. Martignon, 492 F.3d 140 (2d Cir. 2007).
37. Penn Central Transportation Co. v. New York City, 438 U.S. 104 (1978).
38. Kesselheim AS, Outterson K. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals. Health Aff (Millwood). 2010;29(9):1689-96.
39. World Economic Forum attendees. Declaration by the pharmaceutical, biotechnology, and diagnostics industries on combating antimicrobial resistance [Internet]. London: Review on Antimicrobial Resistance; 2016 Jan 21 [cited 2016 Mar 23]. Available from: http://amr-review .org/industry-declaration
40. Hoffman SJ, Outterson K.What will it take to address the global threat of antibiotic resistance? J Law Med Ethics. 2015;43(2):363-8.